Skip to main content
Fig. 6 | Journal for ImmunoTherapy of Cancer

Fig. 6

From: Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts

Fig. 6

Combination therapy of HDAC inhibitor and nivolumab slows growth of TNBC xenograft in hu-CB-BRGS mice. a, Tumor growth curves of MDA-MB-231 TNBC xenografts implanted into hu-CB-BRGS mice that were treated with either control (black), nivolumab (blue), OKI-179 HDACi alone (green), or combination (red). Tumor weights from end of study mice at d30 harvest (control-4 mice/8 tumors; nivolumab-3 mice/6 tumors, OKI-179-1 mouse/2 tumors, combo-2 mice/4 tumors). b, T-cell (hCD45 + CD3+) number (top left), frequency of HLA-DR+ of CD3+ (top right), IFNγ+ of CD8+ (bottom left) and FoxP3+ of CD3+ (bottom right) in TILs or lymph organs of TNBC-implanted humanized mice. c, MFI of Tim3 (left) or PD-1 (right) on T-cells from TILs. d, Frequency of myeloid cells among the hCD45+ population in increased in TILs relative to spleens. Each point represents data from the indicated organ from an individual humanized mouse that was either untreated (−,black), treated with nivolumab (P, blue), OKI-179 (H, green) or both (C, red). P-values: * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001

Back to article page